Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-Up

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

Anna Barata, PhD, Department of Health Outcomes and Behavior, Moffitt Cancer Center, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel; Yescarta) in patients 1-year post-infusion.

Findings from a survey-based study, which were presented in a virtual poster during the 2021 Transplantation and Cellular Therapy Meetings, showed that most patients who received axi-cel continued to experience some degree of toxicity 360 days post-infusion, says Barata. Notably, patients cited fatigue, insomnia, memory problems, and aching muscles/joints as common toxicities. More patients reported any memory problems at day 360 compared with prior to axi-cel, says Barata. However, symptoms such as decreased appetite, dry mouth, and constipation were reportedly improved by day 360 compared with baseline.

As such, long-term screening for symptoms is important to ensure patients receive early supportive care as needed, concludes Barata.

Related Videos
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS
Expert on DLBCL
Tycel Phillips, MD
Expert on ALL
Sohail Dhanji, MD
Eric A. Singer, MD
Sia Daneshmand MD
Fred Saad, MD, FRCS
Benjamin H. Lowentritt, MD, FACS
Related Content